Naringenin and Hesperidin as Promising Alternatives for Prevention and Co-Adjuvant Therapy for Breast Cancer
Maria Beatriz Madureira, Virgínia Márcia Concato, Ellen Mayara Souza Cruz, Juliana Maria Bitencourt de Morais, Fabricio Seidy Ribeiro Inoue, Natália Concimo Santos, Manoela Daniele Gonçalves, Milena Cremer de Souza, Thalita Basso Scandolara, Mariane Fontana Mezoni, Murilo Galvani, Fábio Rodrigues Ferreira Seiva, Carolina Panis, Milena Menegazzo Miranda-Sapla, Wander Rogério Pavanelli
Abstract
L.) fruits are essential sources of bioactive compounds with antioxidant properties, such as flavonoids. These polyphenolic compounds are divided into subclasses, in which flavanones are the most prominent. Among them, naringenin and hesperidin are emerging compounds with anticancer potential, especially for breast cancer (BC). Several mechanisms have been proposed, including the modulation of epigenetics, estrogen signaling, induction of cell death via regulation of apoptotic signaling pathways, and inhibition of tumor invasion and metastasis. However, this information is sparse in the literature and needs to be brought together to provide an overview of how naringenin and hesperidin can serve as therapeutic tools for drug development and as a successful co-adjuvant strategy against BC. This review detailed such mechanisms in this context and highlighted how naringenin and hesperidin could interfere in BC carcinogenesis and be helpful as potential alternative therapeutic sources for breast cancer treatment.